Clinical effect not specified
Source: DDInter
α-Glucosidase inhibitor · Antidiabetic agent
Miglitol reduces the intestinal absorption of starch, dextrin, and disaccharides by inhibiting the action of α-glucosidase in the intestinal brush border. This slows down carbohydrate digestion and absorption, reducing postprandial glucose excursions.
Clinical effect not specified
Source: DDInter
Reduced efficacy of miglitol in controlling postprandial glucose levels.
Monitor blood glucose levels closely. If concurrent use is necessary, consider adjusting the dose of miglitol or pancreatin, or administering them at different times. The clinical significance is generally considered low unless very high doses of pancreatin are used.
10 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team